Recombinant multi-species CILP protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CILP protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Major alterations in the composition of the cartilage extracellular matrix occur in joint disease, such as osteoarthrosis. This gene encodes the cartilage intermediate layer protein (CILP), which increases in early osteoarthrosis cartilage. The encoded protein was thought to encode a protein precursor for two different proteins; an N-terminal CILP and a C-terminal homolog of NTPPHase, however, later studies identified no nucleotide pyrophosphatase phosphodiesterase (NPP) activity. The full-length and the N-terminal domain of this protein was shown to function as an IGF-1 antagonist. An allelic variant of this gene has been associated with lumbar disc disease. [provided by RefSeq, Sep 2010]
The Alternative Names of target: 9830114D16,C130036G17Rik,CILP,CILP-1,CILP1,Cartilage intermediate layer protein 1,Cartilage intermediate-layer protein,Cilp,HsT18872

Target products collectionGo to CILP products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-SE0779-Ag-1/ GM-Tg-hg-SE0779-Ag-2 Human CILP protein Human
GM-Tg-rg-SE0779-Ag-1/ GM-Tg-rg-SE0779-Ag-2 Rat CILP protein Rat
GM-Tg-mg-SE0779-Ag-1/ GM-Tg-mg-SE0779-Ag-2 Mouse CILP protein Mouse
GM-Tg-cynog-SE0779-Ag-1/ GM-Tg-cynog-SE0779-Ag-2 Cynomolgus/Rhesus macaque CILP protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-SE0779-Ag-1/ GM-Tg-felg-SE0779-Ag-2 Feline CILP protein Feline
GM-Tg-cang-SE0779-Ag-1/ GM-Tg-cang-SE0779-Ag-2 Canine CILP protein Canine
GM-Tg-bovg-SE0779-Ag-1/ GM-Tg-bovg-SE0779-Ag-2 Bovine CILP protein Bovine
GM-Tg-equg-SE0779-Ag-1/ GM-Tg-equg-SE0779-Ag-2 Equine CILP protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-SE0779-Ag-1/ GM-Tg-hg-SE0779-Ag-2; GM-Tg-rg-SE0779-Ag-1/ GM-Tg-rg-SE0779-Ag-2;
GM-Tg-mg-SE0779-Ag-1/ GM-Tg-mg-SE0779-Ag-2; GM-Tg-cynog-SE0779-Ag-1/ GM-Tg-cynog-SE0779-Ag-2;
GM-Tg-felg-SE0779-Ag-1/ GM-Tg-felg-SE0779-Ag-2; GM-Tg-cang-SE0779-Ag-1/ GM-Tg-cang-SE0779-Ag-2;
GM-Tg-bovg-SE0779-Ag-1/ GM-Tg-bovg-SE0779-Ag-2; GM-Tg-equg-SE0779-Ag-1/ GM-Tg-equg-SE0779-Ag-2
Products Name CILP protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name CILP
Protein Sub-location Secreted Protein/Potential Cytokines
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CILP protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.